December 2010 | Oncology & Biotech News

ASH 2010: Intensified R-ACVBP More Effective and More Toxic Than R-CHOP in Diffuse Large B-Cell Lymphoma

March 09, 2011

Intensified immunochemotherapy with R-ACVBP significantly improved event-free survival, progression-free survival, disease-free survival, and overall survival compared with R-CHOP in younger patients with diffuse large B-cell lymphoma (DLBCL), but at the cost of increased hematologic toxicity.

ASH 2010: Bosutinib Shows Promise as First-line Treatment of Chronic Myelogenous Leukemia

March 09, 2011

Bosutinib (SKI-606) seems poised to join the tyrosine kinase inhibitors (TKIs) imatinib (Gleevec), dasatinib (Sprycel), and nilotinib (Tasigna) as a first-line therapy option for patients with chronic myelogenous leukemia in the chronic phase.

ASH 2010: Multiple Benefits Observed for Bortezomib in Newly Diagnosed Myeloma Patients

March 09, 2011

In patients with newly diagnosed multiple myeloma who are candidates for transplant, bortezomib (Velcade) achieved high complete response (CR) rates during induction, delayed disease progression, and improved overall survival (OS).